What do systematic reviews say?

Inotersen vs placebo

Inotersen showed no clear difference in number of participants experiencing at least one severe adverse event compared with placebo (low certainty).

• Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
  RR 1.48 [0.85, 2.57]
  1 study · 172 participants
  Low